Physicians were aware to varying degrees of the risks associated with retigabine.

Subgroup analyses showed that both the physicians who read the retigabine education letter and those who had prescribed retigabine had better recall of information.

To strengthen risk-minimization efforts for retigabine and following the identification of new emerging risks in 2013, GSK has since sent an updated ‘Dear Healthcare Professional’ letter and initiated another EU survey to assess how effectively specific risks associated with retigabine use are communicated.